Effects of the new ultra-long-acting β2 -AR agonist indacaterol in chronic treatment alone or in combination with the β1 -AR blocker metoprolol on cardiac remodelling.
Rinaldi B1, Donniacuo M, Sodano L, Gritti G, Martuscelli E, Orlandi A, Rafaniello C, Rossi F, Calzetta L, Capuano A, Matera MG.
British journal of pharmacology.Br J Pharmacol.2015 Mar 30. doi: 10.1111/bph.13148. [Epub ahead of print]
BACKGROUND AND PURPOSE: The role and the mechanism of a chronic treatment with indacaterol, a new ultra-long-acting a β2 -AR agonist on the reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1 -AR antagonist, have been investigated in a myocardial infarction (
IL-13 desensitizes β2-adrenergic receptors in human airway epithelial cells through a 15-lipoxygenase/G protein receptor kinase 2 mechanism.
Albano GD1, Zhao J2, Etling EB3, Park SY4, Hu H3, Trudeau JB3, Profita M5, Wenzel SE3.
The Journal of allergy and clinical immunology.J Allergy Clin Immunol.2015 Mar 24. pii: S0091-6749(15)00226-2. doi: 10.1016/j.jaci.2015.02.006. [Epub ahead of print]
BACKGROUND: β2-Adrenergic receptor (β2AR) agonists are critical treatments for asthma. However, receptor desensitization can lead to loss of therapeutic effects. Although desensitization to repeated use of β2-agonists is well studied, type 2 inflammation could also affect β2AR function.OBJECTIVE
The Journal of biological chemistry.J Biol Chem.2015 Mar 13. pii: jbc.M115.644773. [Epub ahead of print]
G protein-coupled receptor (GPCR) kinases (GRKs) play key role in homologous desensitization of GPCRs. It is widely assumed that most GRKs selectively phosphorylate only active GPCRs. Here we show that although this seems to be the case for GRK2/3 subfamily, GRK5/6 effectively phosphorylate inactive